Migraine in Pregnancy
Migraine management in pregnancy is constrained by limited pharmacologic options. The good news: 50-80% of women with migraine without aura improve during pregnancy, particularly in the second and third trimesters, due to sustained high estrogen levels. However, migraine with aura may persist or worsen, and new-onset headache in pregnancy always requires evaluation for secondary causes (preeclampsia, cerebral venous thrombosis, pituitary apoplexy). A structured approach using safe medications and non-pharmacologic interventions is essential.
Bottom Line
- 50-80% improve in pregnancy (especially migraine without aura); 4-8% worsen
- Acute: Acetaminophen is first-line. Metoclopramide for nausea + adjunctive pain effect. Triptans (sumatriptan) may be used when needed — registry data reassuring but not FDA-approved in pregnancy.
- Avoid: NSAIDs (especially >20 weeks — premature ductus closure), ergots (absolutely contraindicated — uterotonic), valproate (teratogenic)
- Prevention: Propranolol or metoprolol first-line; magnesium supplementation; GON blocks with bupivacaine
- Non-pharmacologic: Biofeedback, relaxation, acupuncture, consistent sleep/hydration, nerve blocks — prioritize these in pregnancy
- Red flags: New headache phenotype, sudden onset, visual symptoms beyond typical aura, hypertension, or postpartum headache — evaluate for preeclampsia, CVT, RCVS
Natural History in Pregnancy
- First trimester: Migraine often persists or worsens (estrogen still fluctuating, nausea/vomiting triggers)
- Second and third trimesters: Sustained high estrogen leads to improvement in 50-80% of women with migraine without aura
- Migraine with aura: Less likely to improve; may persist or present for the first time in pregnancy
- Postpartum: High recurrence rate (within first week in ~50%) due to abrupt estrogen fall; breastfeeding may be partially protective
Secondary Headache Evaluation
Red Flags in Pregnant Patients
- Preeclampsia: New headache + hypertension (≥140/90) + proteinuria after 20 weeks. Headache is present in ~70% of eclampsia cases. Check BP, urinalysis, labs (LDH, platelets, LFTs).
- Cerebral venous thrombosis: Hypercoagulable state of pregnancy. Progressive headache, seizures, focal deficits. MRI + MRV.
- RCVS (reversible cerebral vasoconstriction syndrome): Thunderclap headaches, often postpartum. CTA or MRA shows segmental vasoconstriction.
- Pituitary apoplexy: Pituitary enlarges in pregnancy; hemorrhage into adenoma causes sudden severe headache + visual field loss + hormonal crisis.
- Posterior reversible encephalopathy syndrome (PRES): Often accompanies eclampsia. Occipital-predominant edema on MRI.
- Imaging: MRI without gadolinium is preferred. CT with abdominal shielding is acceptable for acute emergencies. Gadolinium should be avoided (crosses placenta).
Acute Treatment
| Agent | Safety | Notes |
|---|---|---|
| Acetaminophen | First-line throughout pregnancy | 1000 mg PO. Modest efficacy for migraine alone; more effective combined with metoclopramide. Safe in all trimesters. |
| Metoclopramide 10 mg | Safe (preferred antiemetic) | Antiemetic + modest analgesic effect via dopamine antagonism. Can be given IV/IM in ED. No teratogenicity signal. |
| Ondansetron 4-8 mg | Probably safe; some concern for cardiac defects at high doses in first trimester | Use if metoclopramide insufficient. Minimal headache benefit but controls nausea. |
| Sumatriptan | Pregnancy registry data reassuring (no increased malformations); not FDA-approved in pregnancy | Norwegian Registry (>1,000 exposures): no increased risk of malformations. Swedish registry concordant. Use when acetaminophen + metoclopramide fails. Most data are for sumatriptan specifically. |
| NSAIDs (ibuprofen, naproxen) | Avoid after 20 weeks (premature ductus arteriosus closure, oligohydramnios). Limited use in first/early second trimester. | FDA warning (2020) against NSAID use after 20 weeks. Short courses before 20 weeks are likely safe. |
| Magnesium IV (1-2 g) | Safe | Used in ED for acute migraine; also used for preeclampsia prophylaxis. Dual purpose in pregnant migraineurs. |
| Nerve blocks (GON) | Safe (bupivacaine or lidocaine only, no steroid) | One of the best options for refractory attacks in pregnancy. Can repeat every 2-4 weeks. |
Absolutely Contraindicated
- Ergotamine / dihydroergotamine: Uterotonic effects — risk of uterine contractions and fetal distress. Absolutely contraindicated in pregnancy.
- Gepants and ditans: No pregnancy data. Avoid until safety data emerge.
- CGRP mAbs: No human pregnancy data. CGRP is involved in placental development. Discontinue before conception or as soon as pregnancy is confirmed. Washout varies by half-life (erenumab ~28 days; galcanezumab/fremanezumab ~30 days; eptinezumab longer).
Preventive Treatment
| Agent | Safety in Pregnancy | Notes |
|---|---|---|
| Propranolol | Preferred beta-blocker in pregnancy (most data) | Monitor for fetal bradycardia, IUGR at higher doses. Taper before delivery if possible. Neonatal monitoring for hypoglycemia/bradycardia. |
| Metoprolol | Acceptable alternative | Less placental transfer than propranolol. Same neonatal monitoring. |
| Magnesium oxide 400-600 mg/day | Safe | Modest migraine benefit; also prevents leg cramps. GI side effects (diarrhea) manageable. |
| Riboflavin (B2) 400 mg/day | Safe (water-soluble vitamin) | Mild evidence for migraine prevention; harmless in pregnancy. Yellow urine. |
| Cyproheptadine 4-8 mg | Limited data; used in practice as second-line | Antihistamine/antiserotonergic. Sedation and appetite stimulation. Some practitioners use it based on longstanding clinical experience. |
| GON blocks (serial) | Safe | Bupivacaine without steroid, every 4 weeks. One of the most useful preventive strategies in pregnancy. |
| Acupuncture | Safe | Non-pharmacologic; evidence for migraine prevention comparable to drugs. 10-12 session course. |
Contraindicated for Prevention in Pregnancy
- Valproate: Absolutely contraindicated. 10% major malformation rate (neural tube defects), reduced IQ in exposed children. Category X.
- Topiramate: Associated with oral clefts (2-3x baseline risk). FDA Category D. Avoid.
- CGRP mAbs: No human data; CGRP role in placentation is concerning. Discontinue.
- OnabotulinumtoxinA: FDA Category C. Generally avoided, though limited case series have not shown teratogenicity.
- Candesartan / lisinopril: ACE inhibitors and ARBs are teratogenic (renal agenesis, oligohydramnios). Absolutely contraindicated.
Non-Pharmacologic Approach
Non-Drug Strategies in Pregnancy
- Biofeedback and relaxation training: Level A evidence for migraine prevention. No fetal risk. Teach early in pregnancy for cumulative benefit.
- Cognitive behavioral therapy: Effective for headache management, especially with comorbid anxiety
- Sleep hygiene: Consistent schedule; address pregnancy-related sleep disruption early
- Hydration and regular meals: Particularly important given pregnancy-related nausea and metabolic demands
- Acupuncture: Safe throughout pregnancy; 10-12 sessions as initial course
- Nerve blocks: GON +/- supraorbital blocks with local anesthetic only. Can be repeated every 2-4 weeks as a non-systemic approach.
- Neuromodulation: Cefaly (external trigeminal stimulation) is non-invasive and has no systemic effects; can be used in pregnancy though not specifically studied in this population
Breastfeeding Considerations
- Safe during breastfeeding: Acetaminophen, ibuprofen (returns to safe status postpartum), sumatriptan (minimal breast milk transfer; pump and dump not necessary), propranolol, magnesium
- Probably safe: Metoprolol, nortriptyline (low levels in breast milk), eletriptan (very low breast milk transfer)
- Avoid: Aspirin (high doses), ergots, valproate, topiramate (limited data, potential for infant sedation)
- CGRP therapies: Unknown excretion in breast milk. Most practitioners avoid during breastfeeding given lack of data.
Preconception Counseling
- Review all medications 3-6 months before planned conception
- Taper and discontinue valproate, topiramate, CGRP mAbs, and candesartan/lisinopril
- Transition to pregnancy-safe preventive (propranolol, magnesium, nerve blocks) before conception
- Start folic acid 1-4 mg/day (higher dose if previously on valproate)
- Establish non-pharmacologic strategies early
- Counsel that migraine often improves in second/third trimester
References
- Amundsen S, et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015;11(4):209-219.
- Burch R. Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review. Headache. 2020;60(1):200-216.
- Nezvalova-Henriksen K, et al. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache. 2010;50(4):563-575.
- Wells RE, et al. Navigating migraine management in pregnancy. Curr Pain Headache Rep. 2021;25(11):73.
- MacGregor EA. Migraine in pregnancy and lactation. Neurol Sci. 2014;35(Suppl 1):61-64.